NCT04555148View on ClinicalTrials.gov

COVIDIG (COVID-19 Hyper-ImmunoGlobulin)

PHASE2CompletedINTERVENTIONAL
Enrollment

63

Participants

Timeline

Start Date

September 19, 2020

Primary Completion Date

January 22, 2021

Study Completion Date

April 23, 2021

Conditions
Covid19
Interventions
BIOLOGICAL

GC5131

COVID19 Hyper-Immunoglobulin

OTHER

Placebo

Placebo

Trial Locations (1)

Unknown

Samsung Medical Center, Seoul

Sponsors
All Listed Sponsors
lead

Green Cross Corporation

INDUSTRY